Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allergan's Back In The (M&A) Saddle Again Post Pfizer Breakup

This article was originally published in Scrip

Executive Summary

Allergan PLC never really left the market for biopharmaceutical mergers and acquisitions after it entered into a $160bn merger agreement with Pfizer Inc., but now that the deal has been called off the company is free to buy assets large and small that fit its "growth pharma" focus.

Advertisement

Related Content

Allergan’s Ophthalmology Focus Grows Beyond Restasis And Glaucoma
Allergan’s Tab For Tobira’s NASH Cocktail With Akarna Chaser Tops $1.7bn
Pfizer's Medivation Buyout: One-Off Deal Or Start Of A Biopharma Spending Spree?
Allergan's Fishing For Deals, But Don't Expect A Big Catch

Topics

Advertisement
UsernamePublicRestriction

Register

SC064914

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel